Antral Lesions Characterization of a New Cryoballoon Ablation System in Terms of Local Impedance Drop

NCT05410379 | Completed

• 1 other identifier: MCH 2021-01
• Study Type: observational
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

Atrial fibrillation (AF) is defined as a supraventricular tachyarrhythmia with uncoordinated atrial electrical activation and consequently ineffective atrial contraction. Electrocardiographic characteristics of AF include: irregularly irregular R-R intervals (when atrioventricular conduction is not impaired), absence of distinct repeating P waves, and irregular atrial activations. Different AF classifications have been proposed but, traditionally, four patterns of AF are distinguished, based on presentation, duration, and spontaneous termination of AF episodes. Paroxysmal AF, that terminates spontaneously or with intervention within 7 days of onset. Persistent AF that is continuously sustained beyond 7 days, including episodes terminated by cardioversion (drugs or electrical cardioversion) after \>7 days. Long-standing persistent (continuous AF of \>12 months' duration) when decided to adopt a rhythm control strategy. Permanent AF, that is accepted by the patient and physician, and no further attempts to restore/maintain sinus rhythm will be undertaken. The purpose of this study is to perform assessments of local impedance before and after cryoablation performed with the new POLAR X cryoballoon, in order to characterize the quality of the lesion and possibly to associate it with the acute success and 12 months AF recurrence-free rate.

Conditions

Atrial Fibrillation (AF)

Outcome Measures

Primary Outcomes (1)

• local impedance drop

  The primary endpoint of the study is the local impedance drop, measured as the difference between local impedance recorded by the rhythmic HDx mapping system at baseline and after PVI (pulmonary vein isolation) . For the primary endpoint assessment, impedance data will be analyzed offline and grouped per 4 anatomical segments around each pulmonary vein (PV). Absolute values of local impedance measured at baseline and after PVI, as well as local impedance drops will be also compared according to lesion success and according to the value of conventional predictors of successful cryo-lesions (e.g. TTI ( time to isolation ) \< 60 s).

  6 months

Secondary Outcomes (1)

• failure-free rate at 12 months

  12 months.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Subjects enrolled in the CryoLID study will be clinically indicated for a cryoablation procedure and meet the study inclusion/exclusion criteria

You may qualify if:

• Subjects indicated for the treatment of AF with the cryoablation system according to current and future Guidelines and system indications for use;
• Subjects who are willing and capable of providing informed consent;
• Subjects who are willing and capable of participating in all testing associated with this clinical study at an approved clinical investigational center.
• Subjects whose age is 18 years or above, or who are of legal age to give informed consent specific to state and national law.

You may not qualify if:

• Any known contraindication to an AF ablation or anticoagulation, including those listed in the instructions for use;
• Subjects with indication for treatment of AF that is not according to current and future Guidelines and system indications for use;
• Atrial fibrillation secondary to electrolyte imbalance, thyroid disease, or any other reversible or non-cardiac cause;
• Known or pre-existing severe Pulmonary Vein Stenosis;
• Evidence of myxoma, LA ( left atrium) thrombus or intracardiac mural thrombus;
• Previous cardiac surgery (e.g. ventriculotomy or atriotomy, CABG (Coronary artery bypass graft surgery ), PTCA ( Percutaneous transluminal coronary angioplasty), stent procedure) within 90 days prior to enrollment;
• Implantable cardiac device procedures ,e.g. PM (pacemaker), ICD( implantable cardioverter defibrillators), CRT within 30 days prior to enrollment;
• Implanted Left Atrial Appendage Closure device prior to the index procedure;
• Interatrial baffle, closure device, patch, or patent foramen ovale (PFO) occluder;
• Subjects with severe valvular disease OR with a prosthetic - mechanical or biological
• \- heart valve (not including valve repair and annular rings);
• Presence of any pulmonary vein stents;
• Active systemic infection;
• Vena cava embolic protection filter devices and/ or known femoral thrombus;
• Any previous history of cryoglobulinemia;

Sponsors & Collaborators

• Maria Cecilia Hospital: lead

Study Sites (1)

MCH

Cotignola, Ravenna, 48033, Italy

Location

MeSH Terms

Conditions

Atrial Fibrillation

Condition Hierarchy (Ancestors)

Arrhythmias, Cardiac; Heart Diseases; Cardiovascular Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 1, 2022
• First Posted: June 8, 2022
• Study Start: September 15, 2021
• Primary Completion: March 15, 2023
• Study Completion: March 15, 2023
• Last Updated: September 7, 2023

Record last verified: 2023-05

Data Sharing

• IPD Sharing: Will not share

Locations

IT (1)